StockData
Retension Pharmaceuticals, Inc. logo

Retension Pharmaceuticals, Inc. (RTSN) stock

RTSNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 18, 2026
$10.51−2.50 (-19.22%)

Close on Nov 20, 2026Market cap $8.49MP/E –Yield –

Retension Pharmaceuticals net income

Net income is the profit left for shareholders after every expense, interest and tax.

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$5.92M–
Q2 FY2026Jun 30, 2026-$4.14M–
Q1 FY2026Mar 31, 2026-$3.38M–
Q3 FY2025Sep 30, 2025-$1.48M–
Q2 FY2025Jun 30, 2025-$1.23M–
Q1 FY2025Mar 31, 2025-$656.50K–

More Retension Pharmaceuticals figures

See a number that looks wrong?